Zoledronic Acid Inhibits Lipopolysaccharide-Induced Osteoclastogenesis by Suppressing Macrophage NLRP3-Mediated Autophagy PathwayDear Editor,The immunomodulatory effects of antiresorptives, particularly nitrogen-containing bisphosphonates (N-BPs), are often overlooked when evaluating their impact on bone health. This critical aspect of N-BP pharmacology warrants greater attention, as it may play a role beyond inhibiting bone resorption—especially in bone conditions where infection and inflammation are significant contributing factors.(1)The recent study by Yuting Cheng et al. provides valuable insights by demonstrating that low concentrations of zoledronic acid exert anti-inflammatory effects, reducing autophagy in macrophages through suppression of the NLRP3 pathway and downregulation of IL-1β levels.(2) While these findings are compelling, the study would greatly benefit from clarification regarding the clinical relevance of the zoledronic acid doses used in their in vitro and animal models. Specifically, indicating whether such low concentrations could be the norm in patients receiving intravenous or oral bisphosphonate preparations would enhance the translational significance of their results and provide valuable clinical context.